Certest Presents Newly-Released SARS-CoV-2 Diagnostic Products at AACC Clinical Lab Expo
|
By LabMedica International staff writers Posted on 29 Sep 2021 |
|
Image: VIASURE Real Time PCR Detection Kit (Photo courtesy of CerTest Biotec)
CerTest Biotec (Zaragoza, Spain) introduced all the new releases developed by the company in recent months, especially its products focused on the diagnosis of SARS-CoV-2, at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.
Dedicated to achieving better health through laboratory medicine, the American Association for Clinical Chemistry, AACC, brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science.
Among its new releases highlighted by CerTest at AACC 2021 were the VIASURE Tropical Panel I Real Time PCR Detection Kit designed for the specific and differentiation of Zika (ZIKV), Dengue (DENV), Chikungunya (CHIKV), West Nile (WNV), Yellow fever (YFV) and/or Mayaro (MYV) viruses; and the FOB Turbilatex non-invasive immunological test for bowel cancer screening.
CerTest’s new products for the diagnosis of SARS-CoV-2 that were exhibited at the event included the CerTest CLIA SARS-CoV-2 Plate which is an antigen detection product; the CerTest SARS-CoV-2 one step card test which is a colored chromatographic immunoassay for the qualitative detection of SARS-CoV-2 from nasopharyngeal swab samples from patients with sign and symptoms of COVID-19 infection; and the VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit for the qualitative detection of RNA from genetic mutations in the S gene (P681R, L452R and E484Q) from positive SARS-CoV-2 nasopharyngeal samples.
CerTest also used the event as a launching pad for its new Business Units: CerTest CLIA, BioSynProbes and CerTest Vaccines, which were represented at the company’s booth. According to the company, the new business units will complete the portfolio of comprehensive solutions not only for the diagnosis of infectious diseases, but also in the manufacturing processes of clinical tests and disease cure.
Related Links:
CerTest Biotec
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Slide Scanner System
NanoZoomer S540MD
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Latest AACC 2021 News
- Study Showing Differing COVID-19 Antibody Profiles Among Vaccinated and Naturally Infected Individuals Presented at AACC 2021
- Study Reveals Varying Antibody Responses and Adverse Reactions Among Recipients of Different COVID-19 Vaccines
- Novel Study on Performance of Coronavirus Tests in Children Presented at 2021 AACC Annual Scientific Meeting
- New Rapid Test That Identifies Deteriorating COVID-19 Patients with Greater Accuracy than Existing Tests Presented at AACC 2021
- New Blood Test for Occupational Stress Identifies Healthcare Professionals Burned out from COVID-19 Pandemic
- New Non-Invasive Saliva Test for Early and Accurate Detection of Prostate Cancer Presented at AACC 2021
- New Non-Invasive Blood Test for Colon Cancer Presented at 2021 AACC Annual Scientific Meeting
- Study Establishing Accurate Reference Intervals for Pregnant Patients Presented at AACC 2021
- New Test that Measures Antibodies in Girls Who Have Received HPV Vaccine Presented at AACC 2021
- Novel Insights on COVID-19 Vaccines and Virus Evolution, AI in the Clinic, and Miniaturization of Diagnostic Platforms Explored at AACC 2021
- Seegene Unveils New STARlet-AIOS All-in-One Solution for All Molecular Testing at AACC 2021
- Group K Diagnostics Demonstrates KromaHealth Kit that Enables Lab-Quality Results at Point-of-Care
- NGeneBio Showcases NGS-Based Oncology/Genetic Diseases Kits and NGenePlex nCoV qRT-PCR Kit Against COVID-19
- Visby Medical Presents New Portable PCR COVID-19 Test Kit at 2021 AACC Annual Scientific Meeting & Clinical Lab Expo
- Fluxergy Introduces First-of-Its-Kind Multi-Modal Laboratory Platform That Diagnoses COVID-19 On-Site in 60 Minutes
- Mammoth Biosciences Presents AACC 2021 Disruptive Technology Award Finalist CRISPR-Based Detection Platform
Channels
Clinical Chemistry
view channel
UK Project Advances Blood-Based Dementia Testing Toward Routine Clinical Care
Dementia is the leading cause of death in the UK, accounting for almost one in eight deaths, with more than 72,000 people dying from dementia, including Alzheimer’s disease, in 2025. Despite this burden,... Read more
Noninvasive AI-Enabled Raman Probe Distinguishes Skin Cancers from Normal Tissue
Skin cancer is the most common cancer in the United States and among the most common worldwide. Nearly 1.5 million new cases were diagnosed globally in 2024, including nearly 340,000 melanomas.... Read more
Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders
Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more
Molecular Diagnostics
view channel
Facilitated Cascade Program Increases Genetic Testing in Hereditary Cancer Families
Hereditary cancer risk can extend beyond an individual patient to parents, siblings, and children. Although BRCA1 and BRCA2 mutations are linked to elevated risks of breast, ovarian, prostate, and other... Read more
Urine-Based RNA Improves Bladder Cancer Detection and Monitoring
Bladder cancer affects about 85,000 people in the United States each year and is prone to recurrence. Diagnosis and surveillance commonly rely on cystoscopy, an endoscopic examination that can miss up... Read more
Hematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Routine Newborn Blood Spots Can Measure GBS Antibody Levels
Group B Streptococcus (GBS) can cause serious infections in newborns. Protecting infants remains challenging because immune protection may depend on antibodies transferred from mother to baby before birth.... Read more
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
Microbiology
view channel
Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
Fungal bloodstream infections pose a major threat to hospitalized patients. Candida species cause most invasive fungal infections worldwide and are among the leading causes of hospital-acquired bloodstream... Read more
FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read morePathology
view channel
Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
Glioma brain tumors are highly infiltrative and can extend into nearby healthy brain tissue, making tumor margins difficult to define during surgery. Residual tumor cells may contribute to recurrence and... Read more
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read more
Technology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read more
Industry
view channel
Collaboration Advances Automated Benchtop Platform for Routine Blood Testing
Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Expanded Partnership Supports AI Biomarker Validation and Clinical Trial Deployment
CellCarta (Montreal, Canada) and Imagene AI (Miami, FL, USA) have expanded their collaboration to provide biopharma companies with a coordinated pathway for biomarker strategy, assay development, validation,... Read more
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more